Daniel R. Hart
Overview
Daniel R. Hart received an average of $1M in total compensation, including $393K in salary, at Peregrine Pharmaceuticals from 2019 to 2023.
Source: SEC filings on August 28, 2023, August 29, 2022, August 27, 2021, August 27, 2020, and August 21, 2019.
Related executives
We found 13 more executives who work or worked at Peregrine Pharmaceuticals.
Nicholas Green
Peregrine Pharmaceuticals
Chief Executive Officer
Mark Ziebell
Peregrine Pharmaceuticals
General Counsel
Matthew Kwietniak
Peregrine Pharmaceuticals
Chief Commercial Officer
Richard Richieri
Peregrine Pharmaceuticals
Chief Operations Officer
Richard Hancock
Peregrine Pharmaceuticals
Chief Executive Officer
Roger Lias
Peregrine Pharmaceuticals
Chief Executive Officer
Stephen Hedberg
Peregrine Pharmaceuticals
Principal Financial Officer and Principal Accounting Officer
Paul Lytle
Peregrine Pharmaceuticals
Chief Financial Officer
News
Peregrine Pharmaceuticals CEO Nicholas Green's 2023 pay rises 5% to $6.5M
August 28, 2023
Peregrine Pharmaceuticals CEO Nicholas Green's 2022 pay jumps 117% to $6.2M
August 29, 2022
Peregrine Pharmaceuticals CEO Nicholas Green receives $2.8M in 2021
August 27, 2021
Peregrine Pharmaceuticals General Counsel Mark Ziebell's 2020 pay jumps 124% to $1.1M
August 27, 2020
Peregrine Pharmaceuticals CEO Roger Lias' 2019 pay jumps 25% to $880K
August 21, 2019